Literature DB >> 32021505

Efficacy of Eye Movement Desensitization and Reprocessing on the Quality of Life in Patients with Major Depressive Disorder: A Randomized Clinical Trial.

Abdolhadi Jahanfar1, Zhila Fereidouni2, Mohammad Behnammoghadam1, Azizallah Dehghan3, Somayeh Bashti1.   

Abstract

INTRODUCTION: The present study was conducted with the aim of investigating the efficacy of eye movement desensitization and reprocessing (EMDR) on the quality of life (QOL) in patients with major depressive disorder (MDD).
METHODS: This is a randomized clinical trial study that investigated the efficacy of EMDR on the QOL in patients with MDD. In this study, all patients suffered from psychological trauma were currently in a major depressive episode and had a history of depression. 70 patients with MDD were selected through convenience sampling. Patients were then assigned to two groups of intervention and control (35 patients in each group). The assignment was performed randomly. For the intervention group, EMDR were performed in eight 90 mins sessions over 3 weeks. For the control group, no intervention was considered. Data on the QOL were collected using the WHO Quality of Life-BREF instrument before and after the treatment, and analysed using descriptive tests, paired t-test, independent t-test, and chi-square with SPSS v19.
RESULTS: This study showed that the QOL in all its domains (physical health, psychological health, social relationships and environments) was significantly improved in patients with MDD in the intervention group after 8 sessions of EMDR. The post-treatment effect for the EMDR condition was 2.11, with a confidence interval of 1.3 to 2.7. Another finding of this study was that there was a statistically significant difference in the QOL scores in patients in the control group before and after the treatment; however, the mean difference in the intervention group was more than the control.
CONCLUSION: The results of this study showed that EMDR were effective on the QOL in patients with major depressive disorder, and improved individuals' QOL and all its domains. Treatment team members may use this technique as an effective and supportive one to improve the QOL in patients.
© 2020 Jahanfar et al.

Entities:  

Keywords:  eye movement desensitization and reprocessing; major depressive disorder; quality of life

Year:  2020        PMID: 32021505      PMCID: PMC6955614          DOI: 10.2147/PRBM.S232589

Source DB:  PubMed          Journal:  Psychol Res Behav Manag        ISSN: 1179-1578


  20 in total

1.  Addressing the burden of heart failure in Australia: the scope for home-based interventions.

Authors:  P Davidson; S Stewart; D Elliott; J Daly; A Sindone; J Cockburn
Journal:  J Cardiovasc Nurs       Date:  2001-10       Impact factor: 2.083

2.  Escitalopram in the treatment of anxiety symptoms associated with depression.

Authors:  Borwin Bandelow; Henning F Andersen; Ornah T Dolberg
Journal:  Depress Anxiety       Date:  2007       Impact factor: 6.505

Review 3.  Quality of life: the ultimate outcome measure of interventions in major depressive disorder.

Authors:  Waguih William IsHak; Jared Matt Greenberg; Konstantin Balayan; Nina Kapitanski; Jessica Jeffrey; Hassan Fathy; Hala Fakhry; Mark Hyman Rapaport
Journal:  Harv Rev Psychiatry       Date:  2011 Sep-Oct       Impact factor: 3.732

4.  Efficacy of Eye Movements Desensitization and Reprocessing on the Quality of Life of the Patients with Myocardial Infarction.

Authors:  Tahmineh Salehian; Saidzaker Saeedinejad; Mohammad Behnammoghadam; Mohsen Shafiee; Sima Mohammadhossini; Zargham Behnammoghadam; Aziz Behnammoghadam; Soheil Ebrahimpour; Akvan Paymard
Journal:  Glob J Health Sci       Date:  2016-10-01

5.  Depression and perceptions about heart failure predict quality of life in patients with advanced heart failure.

Authors:  Claire N Hallas; Jo Wray; Panayiota Andreou; Nicholas R Banner
Journal:  Heart Lung       Date:  2010-04-08       Impact factor: 2.210

6.  Suicidality in pediatric patients treated with antidepressant drugs.

Authors:  Tarek A Hammad; Thomas Laughren; Judith Racoosin
Journal:  Arch Gen Psychiatry       Date:  2006-03

Review 7.  Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review.

Authors:  R Kathryn McHugh; Sarah W Whitton; Andrew D Peckham; Jeffrey A Welge; Michael W Otto
Journal:  J Clin Psychiatry       Date:  2013-06       Impact factor: 4.384

8.  Cross-national epidemiology of DSM-IV major depressive episode.

Authors:  Evelyn Bromet; Laura Helena Andrade; Irving Hwang; Nancy A Sampson; Jordi Alonso; Giovanni de Girolamo; Ron de Graaf; Koen Demyttenaere; Chiyi Hu; Noboru Iwata; Aimee N Karam; Jagdish Kaur; Stanislav Kostyuchenko; Jean-Pierre Lépine; Daphna Levinson; Herbert Matschinger; Maria Elena Medina Mora; Mark Oakley Browne; Jose Posada-Villa; Maria Carmen Viana; David R Williams; Ronald C Kessler
Journal:  BMC Med       Date:  2011-07-26       Impact factor: 8.775

9.  The Effect of Eye Movement Desensitization and Reprocessing (EMDR) on the severity of suicidal thoughts in patients with major depressive disorder: a randomized controlled trial.

Authors:  Zhila Fereidouni; Mohammad Behnammoghadam; Abdolhadi Jahanfar; Azizallah Dehghan
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-27       Impact factor: 2.570

Review 10.  Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.

Authors:  Halle R Amick; Gerald Gartlehner; Bradley N Gaynes; Catherine Forneris; Gary N Asher; Laura C Morgan; Emmanuel Coker-Schwimmer; Erin Boland; Linda J Lux; Susan Gaylord; Carla Bann; Christiane Barbara Pierl; Kathleen N Lohr
Journal:  BMJ       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.